Cargando…
The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer
Mutations in the epidermal growth factor receptor (EGFR) have been implicated in nearly one-third of non-small-cell lung cancers. For patients harboring non-traditional mutations, genomic and transcriptomic sequencing can help direct treatment. As cancer genomics evolves, novel driver mutations cont...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208280/ https://www.ncbi.nlm.nih.gov/pubmed/37234142 http://dx.doi.org/10.7759/cureus.38059 |
_version_ | 1785046634534535168 |
---|---|
author | Ramanathan, Siddharth Shen, Nathan Kestin, Larry Balaraman, Savitha |
author_facet | Ramanathan, Siddharth Shen, Nathan Kestin, Larry Balaraman, Savitha |
author_sort | Ramanathan, Siddharth |
collection | PubMed |
description | Mutations in the epidermal growth factor receptor (EGFR) have been implicated in nearly one-third of non-small-cell lung cancers. For patients harboring non-traditional mutations, genomic and transcriptomic sequencing can help direct treatment. As cancer genomics evolves, novel driver mutations continue to be uncovered. We report on a unique EGFR-GRB2 fusion in a 48-year-old female never-smoker. This patient presented with stage IV lung adenocarcinoma (T2aN3M1) with metastatic disease in the iliac wing and liver. Despite systemic treatment, this patient continued to progress. On whole transcriptome sequencing, this patient was found to have a novel EGFR-GRB2 RNA fusion transcript similar to other EGFR fusions described in the literature. After treatment with osimertinib, this patient experienced remarkable clinical and radiological improvements. We believe that, especially for patients with metastatic lung cancer, the presence of novel driver mutations should be investigated. Potentially, patients harboring similar mutations may demonstrate analogous improvements with targeted treatment using the most recent generation of tyrosine kinase inhibitors. |
format | Online Article Text |
id | pubmed-10208280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-102082802023-05-25 The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer Ramanathan, Siddharth Shen, Nathan Kestin, Larry Balaraman, Savitha Cureus Oncology Mutations in the epidermal growth factor receptor (EGFR) have been implicated in nearly one-third of non-small-cell lung cancers. For patients harboring non-traditional mutations, genomic and transcriptomic sequencing can help direct treatment. As cancer genomics evolves, novel driver mutations continue to be uncovered. We report on a unique EGFR-GRB2 fusion in a 48-year-old female never-smoker. This patient presented with stage IV lung adenocarcinoma (T2aN3M1) with metastatic disease in the iliac wing and liver. Despite systemic treatment, this patient continued to progress. On whole transcriptome sequencing, this patient was found to have a novel EGFR-GRB2 RNA fusion transcript similar to other EGFR fusions described in the literature. After treatment with osimertinib, this patient experienced remarkable clinical and radiological improvements. We believe that, especially for patients with metastatic lung cancer, the presence of novel driver mutations should be investigated. Potentially, patients harboring similar mutations may demonstrate analogous improvements with targeted treatment using the most recent generation of tyrosine kinase inhibitors. Cureus 2023-04-24 /pmc/articles/PMC10208280/ /pubmed/37234142 http://dx.doi.org/10.7759/cureus.38059 Text en Copyright © 2023, Ramanathan et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Oncology Ramanathan, Siddharth Shen, Nathan Kestin, Larry Balaraman, Savitha The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer |
title | The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer |
title_full | The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer |
title_fullStr | The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer |
title_full_unstemmed | The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer |
title_short | The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer |
title_sort | treatment of a novel epidermal growth factor receptor (egfr)-grb2 genetic mutation using osimertinib in metastatic non-small cell lung cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208280/ https://www.ncbi.nlm.nih.gov/pubmed/37234142 http://dx.doi.org/10.7759/cureus.38059 |
work_keys_str_mv | AT ramanathansiddharth thetreatmentofanovelepidermalgrowthfactorreceptoregfrgrb2geneticmutationusingosimertinibinmetastaticnonsmallcelllungcancer AT shennathan thetreatmentofanovelepidermalgrowthfactorreceptoregfrgrb2geneticmutationusingosimertinibinmetastaticnonsmallcelllungcancer AT kestinlarry thetreatmentofanovelepidermalgrowthfactorreceptoregfrgrb2geneticmutationusingosimertinibinmetastaticnonsmallcelllungcancer AT balaramansavitha thetreatmentofanovelepidermalgrowthfactorreceptoregfrgrb2geneticmutationusingosimertinibinmetastaticnonsmallcelllungcancer AT ramanathansiddharth treatmentofanovelepidermalgrowthfactorreceptoregfrgrb2geneticmutationusingosimertinibinmetastaticnonsmallcelllungcancer AT shennathan treatmentofanovelepidermalgrowthfactorreceptoregfrgrb2geneticmutationusingosimertinibinmetastaticnonsmallcelllungcancer AT kestinlarry treatmentofanovelepidermalgrowthfactorreceptoregfrgrb2geneticmutationusingosimertinibinmetastaticnonsmallcelllungcancer AT balaramansavitha treatmentofanovelepidermalgrowthfactorreceptoregfrgrb2geneticmutationusingosimertinibinmetastaticnonsmallcelllungcancer |